Related references
Note: Only part of the references are listed.Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment
Sun Yoo et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Liver biopsy findings in patients on immune checkpoint inhibitors
Justine V. Cohen et al.
MODERN PATHOLOGY (2021)
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
Stijn J. De Keukeleire et al.
IMMUNOTHERAPY (2021)
A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells
Ikue Sekai et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2021)
Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes
Yoh Zen et al.
HISTOPATHOLOGY (2020)
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection
Ana Pertejo-Fernandez et al.
LUNG CANCER (2020)
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study
Tomoko Kobayashi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage
Ryo Fukuda et al.
INTERNAL MEDICINE (2020)
Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
Pei-Chang Lee et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies
Yasuto Yoneshima et al.
LUNG CANCER (2019)
PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions
Hikari Okamura et al.
JOURNAL OF AUTOIMMUNITY (2019)
Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study
Edward Gane et al.
JOURNAL OF HEPATOLOGY (2019)
The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection
Yasuteru Kondo et al.
SCIENTIFIC REPORTS (2019)
Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity
Takeshi Namiki et al.
JOURNAL OF DERMATOLOGY (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Guillaume Manson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Koichi Sato et al.
LUNG CANCER (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy
Sagun Parakh et al.
ONCOLOGIST (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report
Helen M. McGuire et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury
F. Gelsomino et al.
ANNALS OF ONCOLOGY (2017)
Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab
Ryota Tanaka et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2017)
Severe hepatitis under combined immunotherapy: Resolution under corticosteroids plus anti-thymocyte immunoglobulins
Iris Spaenkuch et al.
EUROPEAN JOURNAL OF CANCER (2017)
Histopathology of pembrolizumab-induced hepatitis: a case report
Karina Aivazian et al.
PATHOLOGY (2017)
Hepatitis C virus has a genetically determined lymphotropism through co-receptor B7.2
Chia-Lin Chen et al.
NATURE COMMUNICATIONS (2017)
Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma
Matteo Simonelli et al.
IMMUNOTHERAPY (2016)
PD-L1+ MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
Tomoaki Iwata et al.
SCIENTIFIC REPORTS (2016)
Differential Expression of CX3CL1 in Hepatitis B Virus-Replicating Hepatoma Cells Can Affect the Migration Activity of CX3CR1+ Immune Cells
Yasuteru Kondo et al.
JOURNAL OF VIROLOGY (2015)
HCV Infection Enhances Th17 Commitment, Which Could Affect the Pathogenesis of Autoimmune Diseases
Yasuteru Kondo et al.
PLOS ONE (2014)
Hepatitis B Virus Replication Could Enhance Regulatory T Cell Activity by Producing Soluble Heat Shock Protein 60 From Hepatocytes
Yasuteru Kondo et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Share Paper
